Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By afschroeder • March 25, 2026

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F. Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). Adv Ther. 2026 Mar 24. doi: 10.1007/s12325-026-03514-6. Epub ahead of print. PMID: 41874851.

Tags: COPD, Dual PDE3, ensifentrine, nebulized therapy, PDE4 Inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Neutrophil Transcriptomic Changes in Severe Sterile Vasoplegic Syndrome Resemble a Distinct Molecular Subtype of Septic Shock

Siletz AE, Kelly-Scumpia KM, Scumpia PO, Street K, Ragkousis V, Shirazi R, Sanaiha Y, Do TH, Shemin R, Kwon M, Crager S, Benharash P, Cryer[...]

Catheter Ablation for Supraventricular Tachyarrhythmias in Adults With Total Cavopulmonary Connection Fontan Palliation

Kamp AN, Moore JP, Alvarado C, Shay V, Ceresnak SR, Bessiere F, Hale B, LaPage MJ, Chang PM, Pilcher TA, Kilinc O, Al-Mousily M, von[...]

Kawasaki Disease in Adults: A Call to Action to Manage Lifelong Coronary Risk

Burns JC, Budoff MJ, Gluckman TJ, Mehran R, Brindis RG, O'Gara PT, Akagi T, Bhatt J, Gordon JB, Newburger JW. Kawasaki Disease in Adults: A[...]